Les patients jeunes peuvent tirer un bénéfice du traitement de première ligne par l’ibrutinib plus rituximab Leukemia Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
